<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03061630</url>
  </required_header>
  <id_info>
    <org_study_id>2017-01-006</org_study_id>
    <nct_id>NCT03061630</nct_id>
  </id_info>
  <brief_title>A Prospective Study of Neoadjuvant Chemotherapy With Gemcitabine/Platinum in Muscle-Invasive or Locally-Advanced Urothelial Carcinoma of Bladder</brief_title>
  <official_title>SAMSUNG MEDICAL CENTER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previously-untreated, high-risk (&gt;T3 and/or N+) muscle-invasive bladder cancer (MIBC)&#xD;
      cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. On day 1&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening numbers are endowed to all patients who sign the informed consent forms. These&#xD;
      screening numbers are used as 'Subject Identification Code&quot; along with patient initials.&#xD;
      Patients withdrawn from the study retain their screening number. New patients must always be&#xD;
      allotted with a new screening number. The study population includes chemotherapy-naïve adults&#xD;
      with high-risk MIBC. Patients who meet all of the inclusion criteria and none of the&#xD;
      exclusion criteria will receive cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on&#xD;
      days 1, 8 and 15. On day 1, adequate hydration and antiemetics are needed. Study chemotherapy&#xD;
      will repeat every 4 weeks on an outpatient basis and continued until disease progression,&#xD;
      unacceptable toxicity, deterioration of clinical condition, patient refusal, or up to 2 or 3&#xD;
      cycles, depending on the operation schedules.&#xD;
&#xD;
      Patients will be seen every 4 weeks. All study subjects will be also eligible to receive best&#xD;
      supportive care (BSC) defined as any standard supportive measures that are not considered a&#xD;
      primary treatment of the disease under study, including the use of growth factors (i.e.&#xD;
      G-CSF) for myelosuppression, bisphosphonates for management of skeletal metastases,&#xD;
      analgesics and transfusion of blood products. BSC will be provided at the discretion of the&#xD;
      investigators.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic response</measure>
    <time_frame>30 months</time_frame>
    <description>to determine the antitumor activity of study treatment in terms of pathologic response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Urinary Bladder</condition>
  <arm_group>
    <arm_group_label>gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. On day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>D1.8.15 : GEMCITABINE 1000MG/M2</description>
    <arm_group_label>gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>D1: CISPLATIN 60G/M2</description>
    <arm_group_label>gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be aged 20 years or more&#xD;
&#xD;
          2. Must have histologically or cytologically proven UC of bladder.&#xD;
&#xD;
          3. Must have histological evidence of high-risk muscle-invasive disease (i.e., T2~ T4) or&#xD;
             clinically N+ disease. They must be considered to have no other treatment options than&#xD;
             radical cystectomy.&#xD;
&#xD;
          4. Must have an ECOG performance status of 0 to 1&#xD;
&#xD;
          5. Must have a life expectancy of 6 months or more&#xD;
&#xD;
          6. At least 2 weeks since the last surgical procedures or biopsies prior to enrolment.&#xD;
             Subjects must have recovered to &lt;Grade 2 from all acute toxicities or toxicity must be&#xD;
             deemed irreversible by the investigator.&#xD;
&#xD;
          7. Adequate marrow function without growth factor support or transfusion dependency&#xD;
&#xD;
          8. Adequate renal function with serum creatinine 1.5 x ULN or a calculated creatinine&#xD;
             clearance ≥ 60 mL/min using the Cockcroft-Gault or MDRD formulas&#xD;
&#xD;
          9. Adequate hepatic function&#xD;
&#xD;
         10. Must agree to use an adequate method of contraception if the patient is sexually&#xD;
             active, during and for 12 weeks after the completion of chemotherapy&#xD;
&#xD;
         11. Written and voluntary informed consent understood, signed and dated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ongoing treatment with an anticancer agent not contemplated in this protocol&#xD;
&#xD;
          2. Radiologic finding consistent with metastatic disease&#xD;
&#xD;
          3. Severe medical or phychological illness that preclude participation to study,&#xD;
             including any history of clinically relevant coronary artery disease or myocardial&#xD;
             infarction within the last 3 years, (NYHA) grade III or greater congestive heart&#xD;
             failure, cerebrovascular attack within the prior year, or current serious cardiac&#xD;
             arrhythmia requiring medication except atrial fibrillation&#xD;
&#xD;
          4. Non-tolerable &gt; Grade 2 neuropathy or evidence of unstable neurological symptoms&#xD;
             within 4 weeks of Cycle 1 Day 1&#xD;
&#xD;
          5. Major surgery, other than diagnostic surgery or transurethral resection, within 4&#xD;
             weeks prior to Cycle 1 Day 1, without complete recovery&#xD;
&#xD;
          6. Double primary cancer of other site(s) or a history of other malignancies, except for&#xD;
             cured ones at the discretion of investigator&#xD;
&#xD;
          7. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic&#xD;
             therapy.&#xD;
&#xD;
          8. Subjects who have exhibited allergic reactions to study treatment&#xD;
&#xD;
          9. Concomitant disease or condition that could interfere with the conduct of the study,&#xD;
             or that would, in the opinion of the Investigator, pose an unacceptable risk to the&#xD;
             subject in this study&#xD;
&#xD;
         10. Subject with legal incapacity or limited legal capacity. Dementia or significantly&#xD;
             altered mental status that would limit the understanding or rendering of informed&#xD;
             consent and compliance with the requirements of this protocol. Unwillingness or&#xD;
             inability to comply with the study protocol for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SEHOON PARK, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SamsungMedicalCenter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SEHOON PARK, MD,PhD</last_name>
    <phone>82-2-2148-7394</phone>
    <email>sh1767.park@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Se Hoon Park, MD</last_name>
      <phone>+82 2 3410 3459</phone>
      <email>hematoma@skku.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 20, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Park, Se-Hoon</investigator_full_name>
    <investigator_title>Samsung Medical Center</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

